Indivior Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Indivior Pharmaceuticals (INDV) filed an S-4 for an all-stock merger with Supernus Pharmaceuticals (SUPN). Each Supernus share will convert to 1.5401 Indivior shares. Indivior plans a $1B special dividend, contingent on merger completion, with a $650M loan to fund it. Post-merger, Indivior will rename to Supernus and trade under SUPN. The deal is expected to close in Q4 2026, subject to approvals.
Anderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $35.69 on 2026-08-27.
Supernus Pharmaceuticals (SUPN) announced a merger with Indivior (INDV) and reported Q2 earnings. Revenue rose 32% to $219M, but net loss was $58M. The all-stock deal, pending approval, is expected to close Q4 2023. Stock closed 3% higher.
Over the past 7 days, alphai's AI scored 2 news stories mentioning INDV (Indivior Pharmaceuticals, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent INDV coverage spans mergers & acquisitions, insider activity and earnings.
In the last 30 days, INDV insiders filed 2 SEC Form 4 transactions — 2 purchases ($108K) and no sales. The most active reporter was Anderson Woodrow D, Chief Accounting Officer, with 2 filings.
Merger creates a larger CNS/OUD company; $1B dividend adds cash pressure and leverage.
Small insider buy by a senior officer may signal confidence but limited market impact.
Indivior will gain a broader drug portfolio and cost‑saving opportunities, but faces integration risk and a larger combined loss profile.
For INDV, the trade centers on deal-premium expectations in an all-stock structure and the probability of achieving synergies.
This is an insider open-market purchase, which can be read as mild positive sentiment but is not a fundamental catalyst by itself.
alphai scores every news story that mentions INDV with an AI model for sentiment and relevance, and aggregates insider trades from Indivior Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Indivior Pharmaceuticals (INDV) filed an S-4 for an all-stock merger with Supernus Pharmaceuticals (SUPN). Each Supernus share will convert to 1.5401 Indivior shares. Indivior plans a $1B special dividend, contingent on merger completion, with a $650M loan to fund it. Post-merger, Indivior will rename to Supernus and trade under SUPN. The deal is expected to close in Q4 2026, subject to approvals.
3 min readAnderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $35.69 on 2026-08-27.
1 min readSupernus Pharmaceuticals (SUPN) announced a merger with Indivior (INDV) and reported Q2 earnings. Revenue rose 32% to $219M, but net loss was $58M. The all-stock deal, pending approval, is expected to close Q4 2023. Stock closed 3% higher.
3 min readMacquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.
6 min readAnderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $36.28 on 2026-08-05.
1 min readIndivior Pharmaceuticals (NASDAQ:INDV) reported Q2 2026 adjusted EPS of $1.15 vs $0.74 expected, and revenue of $343 million vs $284.9 million expected. SUBLOCADE net revenue rose 21% to $253 million. Indivior raised FY2026 revenue guidance to $1.295B-$1.365B and SUBLOCADE guidance to $1.01B-$1.05B. Shares rose 9.22% premarket.
4 min readSupernus Pharmaceuticals and Indivior agreed to merge in a deal valued at about $1.8 billion. Indivior shareholders will receive 0.2683 Supernus shares each, a stated ~58% premium. Supernus shareholders will own ~58% and Indivior ~42%. Closing is expected in H2 2026, pending approvals, with ~$125 million annual cost synergies by end-2027.
3 min readIndivior (INDV) agreed to a tax-free, all-stock merger with Supernus (SUPN). Indivior shareholders will own about 56.5% and Supernus 43.5%. The combined CNS-focused company is expected to close in Q4 2026 and trade on Nasdaq under SUPN. Pro forma: ~$2.2B revenue, $888M adjusted EBITDA, $125M synergies. Indivior Q2 2026: adj. EPS $1.15, revenue $343M.
7 min readSupernus Pharmaceuticals and Indivior are planning an all-stock merger to form a CNS-focused biopharma. The deal is expected to produce pro forma net revenue of $2.2bn and about $125m in annual cost synergies. Supernus brings Qelbree and Gocovri; Indivior brings Sublocade, Suboxone and Opvee. If completed in Q4 2026, the combined firm will trade as SUPN on Nasdaq.
4 min readIndivior and Supernus outlined a proposed tax-free all-stock “merger of equals” between the two companies. Indivior plans to file an SEC Form S-4 with a joint proxy statement/prospectus, and both firms will submit additional SEC documents. Shareholders will receive the definitive joint proxy statement/prospectus when available.
3 min read
